Unique ID issued by UMIN | UMIN000058202 |
---|---|
Receipt number | R000066540 |
Scientific Title | Clinical trial to evaluate the effect of a new skincare formulation (FQWO71W1) on rough skin recovery |
Date of disclosure of the study information | 2025/06/20 |
Last modified on | 2025/06/17 12:03:34 |
Clinical trial to evaluate the effect of a new skincare formulation (FQWO71W1) on rough skin recovery
Clinical trial to evaluate the effect of a new skincare formulation (FQWO71W1) on rough skin recovery
Clinical trial to evaluate the effect of a new skincare formulation (FQWO71W1) on rough skin recovery
Clinical trial to evaluate the effect of a new skincare formulation (FQWO71W1) on rough skin recovery
Japan |
Healthy adults
Not applicable | Adult |
Others
NO
Confirmation of the effect of a new skincare formulation (FQWO71W1) on rough skin recovery
Efficacy
Observation of skin condition after repeated use of a new skincare formulation (FQWO71W1)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Other |
The new skincare formulation (FQWO71W1) and placebo will be applied repeatedly to areas of rough skin
20 | years-old | <= |
60 | years-old | >= |
Male and Female
1)Men and women aged 20 to 60 years at the time of informed consent.
2)Able to visit the testing site and undergo the required examinations on the designated dates.
3)Deemed eligible for participation in this study by the principal investigator.
1)Individuals with severe atopic dermatitis.
2)Individuals receiving hormone replacement therapy.
3)Individuals with a history of allergy to cosmetics or drugs, or those with sensitive skin.
4)Individuals who are pregnant, possibly pregnant, or breastfeeding.
5)Individuals with or suspected of having severe cardiac, renal, or hepatic impairment, or circulatory diseases.
6)Individuals who are currently undergoing or have undergone within the past 3 months treatments that may affect skin function, such as chemical peels, laser treatments, or the use of physician-prescribed medications including hydroquinone, high-concentration vitamin C, and retinoic acid on the forearm.
7)Individuals currently participating in other clinical trials.
8)Individuals with large scars, warts, or rashes on the medial aspect of the forearm.
9)Individuals deemed ineligible by the study investigator.
10
1st name | Riichi |
Middle name | |
Last name | Takahashi |
FANCL Corporation
Research Institute
2440806
12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa
045-820-3612
takahashi_riichi@fancl.co.jp
1st name | Yoko |
Middle name | |
Last name | Imai |
FANCL Corporation
Research Institute
244-0806
12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa
045-820-3539
yoko1607@fancl.co.jp
FANCL Corporation
FANCL Corporation
Profit organization
FANCL Corporation Ethics Committee
12-13, Kamishinano, Totsuka-ku, Yokohama, Kanagawa
045-820-3565
hisaitou@fancl.co.jp
NO
2025 | Year | 06 | Month | 20 | Day |
Unpublished
Preinitiation
2025 | Year | 05 | Month | 23 | Day |
2025 | Year | 06 | Month | 23 | Day |
2025 | Year | 07 | Month | 07 | Day |
2025 | Year | 06 | Month | 17 | Day |
2025 | Year | 06 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066540